- Prev close
- $590.00
- Day range
- $583.44 – $600.84
- Next earnings
- in 86 days
IDEXX rose +1.6% in a record-setting tech-led tape, a move that looks broadly supported but not especially diagnostic ahead of earnings. The setup is mixed because growth and margins remain strong, while the stock still trades at 40.9x earnings and sits -26.3% below its 52-week high.
IDXX
IDEXX LABORATORIES INC
As of Aug 4, 2026
62/100
Worth keeping an eye onHealth ScoreWhy it moved
The primary driver looks market-wide: IDXX gained +1.6% while the S&P 500 rose +1.8% and the Nasdaq 100 rose +3.4%, so the stock actually lagged the strongest part of the tape. It also moved in line with the broader veterinary/med-tech complex, with BSX +1.4% and EW +0.9%, while ISRG jumped +6.2% and SYK fell -1.5%. That pattern says this was not a stock-specific shock; it was a normal session in a strong market, with IDXX participating but not leading.
Volatility read
This looks like ordinary volatility, not a fresh fundamental break. The business is still growing at revenue +13.1% YoY (TTM), latest quarter +14.3% YoY, and EPS +25.6% YoY (TTM), with operating margin at +31.6% and net margin at +24.6%. The valuation is still demanding at PE 40.9, forward PE 35.6, and PEG 3.24 — PEG means P/E divided by growth, so investors are paying 3.24x the growth rate — which means the market is already discounting strong execution. Beta is 1.56, so moves of this size are not unusual for the name; the session fits that profile and does not by itself imply deterioration.
Earnings preview
The next earnings date is 2026-08-04. The facts provided do not include Wall Street revenue or EPS estimates for this print, so I cannot cite a consensus growth or margin forecast this period. What the market is waiting to learn is whether IDEXX can keep revenue growth near the recent +14.3% YoY pace, whether +31.6% operating margin and +24.6% net margin hold up, and whether management reaffirms the long-run innovation and sustainability progress highlighted in the 2025 Corporate Responsibility Report. The available facts also do not show a prior earnings-reaction pattern, so there is no reliable history to anchor around from this set.
This report is for informational and educational purposes only. It does not constitute financial, investment, tax, or legal advice. The platform does not recommend buying or selling any security.
Track IDXX with WhyIHold
Get a plain-English explanation the next time IDEXX LABORATORIES INC makes a big move — so you know whether it's benign or worth your attention.